ENHANCEMENT OF SKIN PERMEABILITY OF ECONAZOLE NITRATE USING NOVEL FLEXISOMAL NANOCARRIERS BY IMPLEMENTING QUALITY BY DESIGN (QBD) APPROACH
Objective: The purpose of this study was an implementation of quality by design (QbD) for the formulation and characterization of econazole nitrate loaded flexisomal nanocarriers (EN-FS) to improve antifungal activity and to enhance skin permeability.
Methods: Initially quality target product profile (QTTP) elements were identified and later critical quality attributes (CQA) elements were defined from QTPP elements. Particle size, entrapment efficiency and deformability index were defined as CQAs. Risk assessment was performed by using fishbone diagram and failure mode and effect analysis (FMEA). Design space was created by using fractional factorial design 25-2 as screening design and 32 full factorial design as optimization design to optimize two variables soya phosphatidylcholine concentration(X1) and sodium deoxycholate concentration (X2).
Results: Optimized batch of EN-FS was 249.5±3.48 nm, with entrapment efficiency of 88.6±0.89 % and deformability index of 31.75±0.98. Zeta potential analysis showed value of-22.5 mV. Morphological analysis by TEM showed spherical shaped flexisomes, which confirmed the vesicular characteristics. The optimized batch of EN-FS was further made into hydrogels by using sepineo P600 as gelling agent. The % drug diffusion of EN-FS hydrogels had shown 24.68%. With higher skin deposition and higher value of zone of inhibition in antifungal study as compared to plain EN hydrogel. CLSM studies indicated deep penetration of EN-FS in skin layers. Lastly control strategy for EN-FS were developed.
Conclusion: It was concluded that EN-FS showed high flexibility and enhanced antifungal activity therefore found to be a potential nanocarriers for drug deposition in skin layers without disturbing skin integrity.
2. US Food and Drug Administration. Guidance for industry: Q8 (R2) pharmaceutical development. Center for Drug Evaluation and Research; 2009.
3. Patel H, Parmar S, Patel B. A comprehensive review on quality by design (QbD) in pharmaceuticals. Development 2013;4:5.
4. Guidance for industry: Q8 pharmaceutical development, US Department of Health and Human Service. FDA, Rockville MD; 2006. Available from: http://www.fda.gov/downloads/ RegulatoryInformation/Guidances/ucm12802.pdf. [Last accessed on 01 Jun 2013].
5. Guidance for industry: Q9 quality risk management, US Department of Health and Human Service FDA, Rockville MD; 2006. Available from: http://www.fda.gov/downloads/ Drugs/../Guidances/ucm073511.pdf [Last accessed on 1 Jun 2013].
6. Guideline IH. Pharmaceutical quality system q10. Current Step; 2008.
7. Mandlik SK, Siras SS, Birajdar KR. Optimization and characterization of sertaconazole nitrate flexisomes embedded in hydrogel for improved antifungal activity. J Liposome Res 2019;29:10-20.
8. Cevc G. Self-regulating smart carriers'for non-invasive and targeted drug delivery. Cell Mol Biol Lett 2002;7:224-5.
9. Patidar A, Thakur DS, Kumar P, Verma JH. A review on novel lipid-based nanocarriers. Int J Pharm Pharm Sci 2010;2:30-5.
10. Jain S, Jain P, Umamaheshwari RB, Jain NK. Transfersomes-a novel vesicular carrier for enhanced transdermal delivery: development, characterization, and performance evaluation. Drug Dev Ind Pharm 2003;29:1013-26.
11. El Zaafarany GM, Awad GA, Holayel SM, Mortada ND. Role of edge activators and surface charge in developing ultra deformable vesicles with enhanced skin delivery. Int J Pharm 2010;397:164-72.
12. Gupta PN, Mishra V, Singh P, Rawat A, Dubey P, Mahor S, et al. Tetanus toxoid?loaded transfersomes for topical immunization. J Pharm Pharmacol 2005;57:295-301.
13. Gungor S, Erdal MS, Aksu B. New formulation strategies in topical antifungal therapy. J Cosmet Dermatol Sci Appl 2013;3:56.
14. Keshri L, Pathak K. Development of thermodynamically stable nanostructured lipid carrier system using central composite design for zero-order permeation of econazole nitrate through epidermis. Pharm Dev Technol 2013;18:634-44.
15. Sharma R, Pathak K. Polymeric nanosponges as an alternative carrier for improved retention of econazole nitrate onto the skin through topical hydrogel formulation. Pharm Dev Technol 2011;16:367-76.
16. Panigrahi KC, Patra CN, Rao MB. Quality by design enabled development of oral self-nano emulsifying drug delivery system of a novel calcimimetic cinacalcet hcl using a porous carrier: in vitro and in vivo characterization. AAPS PharmSciTech. 2019;20:216.
17. Roy S. Quality by design: a holistic concept of building quality in pharmaceuticals. Int J Pharm Biomed Res 2012;3:100-8.
18. Tomba E, Facco P, Bezzo F, Barolo M. Latent variable modeling to assist the implementation of quality-by-design paradigms in pharmaceutical development and manufacturing: a review. Int J Pharm 2013;457:283-97.
19. Stamatis DH. Failure mode and effect analysis: FMEA from theory to execution. ASQ Quality Press; 2003.
20. Nasr M. Risk-based CMC review paradigm. In: Advisory committee for pharmaceutical science meeting; 2004.
21. Lawrence XY. Pharmaceutical quality by design: product and process development, understanding, and control. Pharm Res 2008;25:781-91.
22. Sonar G, Rawat S. Optimization of pantoprazole enteric pellets coating process by Qbd: effect of coating process variables on the intermediate quality of the product and scale-up. Int J Pharm Pharm Sci 2015;7:80-7.
23. Lionberger RA, Lee SL, Lee L, Raw A, Lawrence XY. Quality by design: concepts for ANDAs. AAPS J 2008;10:268-76.
24. Gupta A, Aggarwal G, Singla S, Arora R. Transfersomes: a novel vesicular carrier for enhanced transdermal delivery of sertraline: development, characterization, and performance evaluation. Sci Pharm 2012;80:1061-80.
25. Salama HA, Mahmoud AA, Kamel AO, Abdel Hady M, Awad GA. Brain delivery of olanzapine by intranasal administration of transfersomal vesicles. J Liposome Res 2012;22:336-45.
26. Ahmed TA. Preparation of transfersomes encapsulating sildenafil aimed for transdermal drug delivery: plackett–burman design and characterization. J Liposome Res 2015;25:1-10.
27. Malakar J, Sen SO, Nayak AK, Sen KK. Formulation, optimization and evaluation of transferosomal gel for transdermal insulin delivery. Saudi Pharm J 2012;20:355-63.
28. Jain S, Tiwary AK, Sapra B, Jain NK. Formulation and evaluation of ethosomes for transdermal delivery of lamivudine. AAPS PharmSciTech 2007;8:249.
29. Gonzalez rodriguez ML, Arroyo CM, Cozar Bernal MJ, Gonzalez R PL, Leon JM, Calle M, et al. Deformability properties of timolol-loaded transfersomes based on the extrusion mechanism. Statistical optimization of the process. Drug Development Industrial Pharm 2016;42:1683-94.
30. Mandlik SK, Nandare DS, Joshi MM, Chudiwal PD, Jain KS. Statistical optimization of orodispersible tablets containing telmisartan using factorial design and response surface methodology. Res J Pharm Technol 2009;2:548-51.
31. Joshi SA, Chavhan SS, Sawant KK. Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies. Eur J Pharm Biopharm 2010;76:189-99.
32. Bonacucina G, Cespi M, Palmieri GF. Characterization and stability of emulsion gels based on acrylamide/sodium acryloyldimethyl taurate copolymer. AAPS PharmSciTech 2009;10:368-75.
33. Zheng WS, Fang XQ, Wang LL, Zhang YJ. Preparation and quality assessment of itraconazole transfersomes. Int J Pharm 2012;436:291-8.
34. Janardhan PP, Praveen CS, Vasant GS. Evaluation of wound healing activity of silver sulfadiazine emulgel (1%) in the rat burn wound model and its skin irritation study. Indian Drugs 2012;49:40-3.
35. Bikkad ML, Nathani AH, Mandlik SK, Shrotriya SN, Ranpise NS. Halobetasol propionate-loaded solid lipid nanoparticles (SLN) for skin targeting by topical delivery. J Liposome Res 2014;24:113-23.
36. Sahoo S, Pani NR, Sahoo SK. Effect of microemulsion in topical sertaconazole hydrogel: in vitro and in vivo study. Drug Delivery 2016;23:338-45.
37. Kusuma SA, Abdassah M, Valas BE. Formulation and evaluation of anti-acne gel containing citrus aurantifolia fruit juice using carbopol as gelling agent. Int J Appl Pharm 2018;10:147-52.
38. Hussain A, Samad A, Singh SK, Ahsan MN, Haque MW, Faruk A, et al. Nanoemulsion gel-based topical delivery of an antifungal drug: in vitro activity and in vivo evaluation. Drug Delivery 2016;23:642-57.
39. Verma P, Pathak K. Nanosized ethanolic vesicles loaded with econazole nitrate for the treatment of deep fungal infections through topical gel formulation. Nanomed: Nanotechnol Biol Med 2012;8:489-96.
40. Subongkot T, Wonglertnirant N, Songprakhon P, Rojanarata T, Opanasopit P, Ngawhirunpat T. Visualization of ultradeformable liposomes penetration pathways and their skin interaction by confocal laser scanning microscopy. Int J Pharm 2013;441:151-61.
41. Nayak A, Laha B, Sen K. Development of hydroxyapatite-ciprofloxacin bone-implants using» Quality by design «. Acta Pharm 2011;61:25-36.
42. Shreya AB, Managuli RS, Menon J, Kondapalli L, Hegde AR, Avadhani K, et al. Nano-transfersomal formulations for transdermal delivery of asenapine maleate: in vitro and in vivo performance evaluations. J Liposome Res 2016;26:221-32.
43. Pople PV, Singh KK. Development and evaluation of a topical formulation containing solid lipid nanoparticles of vitamin A. AAPS PharmSciTech 2006;7:E63-9.
This work is licensed under a Creative Commons Attribution 4.0 International License.